SCHEMBL5827709

SCHEMBL5827709

[NH][C@H](CO)Cc1cnc[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.55
KDM4E B2RXH2 2/20 0.53
PMP22 Q01453 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
POLB P06746 1/20 0.53
RECQL P46063 1/20 0.53
HRH4 Q9H3N8 6/20 0.52
HRH3 Q9Y5N1 6/20 0.52
ALDH1A1 P00352 5/20 0.52
NFKB1 P19838 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
THPO P40225 2/20 0.52
GLA P06280 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 3/20 0.50
LMNA P02545 2/20 0.50
APEX1 P27695 2/20 0.50
SLC7A5 Q01650 1/20 0.50
BLM P54132 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidinol SCHEMBL10002446 0.77 HRH4 (0.61) PKMKDM4EPMP22NPSR1POLB
Histidinol SCHEMBL6546332 0.77 HRH4 (0.61) PKMKDM4EPMP22NPSR1POLB
SCHEMBL14390959 0.77 HRH3 (0.61) PKMKDM4EPMP22NPSR1POLB
SCHEMBL15906228 0.77 HRH3 (0.61) PKMKDM4EPMP22NPSR1POLB
Histidinol SCHEMBL407337 0.77 HRH4 (0.61) PKMKDM4EPMP22NPSR1POLB
SCHEMBL6664741 0.77 HRH3 (0.61) PKMKDM4EPMP22NPSR1POLB
Histidinol SCHEMBL29986891 0.76 HRH4 (0.62) PKMKDM4EPMP22NPSR1POLB
SCHEMBL13594976 0.74 HRH3 (0.58) PKMKDM4EPMP22NPSR1POLB
SCHEMBL14652129 0.74 HRH3 (0.58) PKMKDM4EPMP22NPSR1POLB
SCHEMBL20093584 0.74 HRH4 (0.53) PKMKDM4EPMP22NPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109330-B2 Purine inhibitors of cyclin dependent kinase 2 and IκB-α CV THERAPEUTICS, INC. (US) 2006-09-19 US disclosed
EP-1150982-B1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha CV THERAPEUTICS INC (US) 2005-10-12 EP disclosed
US-20050080261-A1 Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha LUM ROBERT T (US) 2005-04-14 US disclosed
US-6790958-B2 ANTIPROLIFERATIVE AGENTS; FUNGICIDES LUM ROBERT T (US) 2004-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080261-A1 Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha IKBKB, NFKB1, CDK4 PKM 908/4885KDM4E 289/4885PMP22 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.